Aicuris (NASDAQ:AICR) FDA Grants Priority Review for Pritelivir NDA
Expert Analysis Aicuris (NASDAQ:AICR) has made a significant stride in the development of pritelivir, a promising therapy targeting refractory herpes simplex virus infections in immunocompromised patients. The FDA’s decision to grant Priority Review to the New Drug Application (NDA) underscores the potential impact this antiviral drug could have on treating resistant HSV cases, where few options exist. This regulatory acceleration suggests that the FDA recognizes the unmet medical need addressed…
